While the direct oral anticoagulants (DOACs) are no longer ‘novel,’ the dilemmas in the evolving field of anticoagulation continue. In this Grand Rounds, we will explore the changing landscape of anticoagulation therapies and thrombophilia testing, including understanding how DOACs can be safely and effectively employed, even in patients with end-stage renal disease. We will also dive into emerging data on new therapeutics targeting different aspects of the coagulation cascade.
Speakers
Margaret Fang, MD, MPH, is professor of Medicine, chief of the Division of Hospital Medicine at UCSF Health, and medical director of the UCSF Anticoagulation Clinic. Her research addresses how to help patients balance the benefits and harms of anticoagulants for stroke and venous thromboembolism. She is the principal investigator of the CVRN VTE and ALTERNATIVE studies, both cohorts of patients with venous thrombosis.
Andrew Leavitt, MD, is a professor in the Departments of Medicine and Laboratory Medicine and director of the UCSF Adult Hemophilia Treatment Center. He is internationally known for his studies of the development of megakaryocytes, large cells in the bone marrow that divide to produce blood platelets.
Tracy Minichiello, MD, is professor of Medicine and chief of the Anticoagulation and Thrombosis Services at the SFVAHCS, a multidisciplinary service that cares for patients on anticoagulation. She developed the first electronic consultation program in anticoagulation and thrombosis for the VA, providing high-level subspecialty consultation to urban and remote veterans and their providers.
Note: Closed captions will be available within 48-72 hours after posting.
Program
Bob Wachter: Introduction
00:02:09-00:14:13 - Margaret Fang, MD, MPH, professor of Medicine, chief of the Division of Hospital Medicine at UCSF Health, medical director of the UCSF Anticoagulation Clinic
00:14:22-00:26:57 - Tracy Minichiello, MD, professor of Medicine, chief of the Anticoagulation and Thrombosis Services at the SFVAHCS
00:27:14-00:49:39 - Andrew Leavitt, MD, professor in the Departments of Medicine and Laboratory Medicine, director of the UCSF Adult Hemophilia Treatment Center
00:50:02-1:02:19 - Q&A
See previous Medical Grand Rounds:
• October 26: Bridging Synthetic Immunology and Genome Editing to Advance CAR-T Cell Therapies
• Bridging Synthetic Imm...
• October 19: Mapping the Clinical and Multi-Omics Terrain to New Horizons in Inflammatory Bowel Disease
• Mapping the Clinical a...
• October 12: Improving Value in Medicine: Health Technology Assessment and Determining the Value of Treatments
• Improving Value in Med...
• October 5: A Learning Journey: Understanding and Improving Equity in Palliative Medicine
• A Learning Journey: Un...
See all UCSF Covid-19 grand rounds, which have been viewed over 3M times, at • UCSF Department of Med... .